Table 3

Changes in BW and WC according to the AMY1-AMY2 rs11185098 genotype

Model 1Model 2Model 3Model 4
Outcomeβ (SE)P valueβ (SE)P valueβ (SE)P valueβ (SE)P value
6 months
 Δ BW−0.78 (0.35)0.027−0.70 (0.35)0.044−0.64 (0.35)0.067−0.67 (0.35)0.056
 Δ WC−1.21 (0.38)0.002−1.06 (0.37)0.005−1.01 (0.37)0.007−1.02 (0.37)0.006
12 months
 Δ BW−1.30 (0.47)0.005−1.21 (0.46)0.009−1.09 (0.46)0.018−1.15 (0.46)0.014
 Δ WC−1.55 (0.49)0.002−1.38 (0.48)0.004−1.31 (0.48)0.007−1.35 (0.48)0.005
18 months
 Δ BW−1.70 (0.52)0.001−1.63 (0.52)0.002−1.55 (0.52)0.003−1.59 (0.52)0.003
 Δ WC−1.51 (0.54)0.005−1.39 (0.53)0.009−1.31 (0.53)0.014−1.39 (0.53)0.009
24 months
 Δ BW−1.34 (0.49)0.006−1.27 (0.49)0.01−1.19 (0.49)0.015−1.23 (0.49)0.012
 Δ WC−1.57 (0.52)0.003−1.43 (0.51)0.005−1.39 (0.51)0.006−1.41 (0.51)0.006
  • β represents changes in outcomes by increasing number of A alleles. Model 1: age, sex, ethnicity, and diet group. Model 2: age, sex, ethnicity, diet group, and value for the respective outcome traits at the baseline examination (either BW or WC). Model 3: age, sex, ethnicity, diet group, BMI at baseline, WC at baseline, and glucose at baseline. Model 4: model 3 + antihypertensive medication use at baseline and lipid-lowering medication use at baseline.